References
- Holstein JD , KovacsP, PatzerO, StumvollM, HolsteinA. The Ser1369Ala variant of ABCC8 and the risk for severe sulfonylurea-induced hypoglycemia in German patients with Type 2 diabetes. Pharmacogenomics13(1) , 5–7 (2012).
- Sato R , WatanabeH, GenmaR et al. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. Pharmacogenomics11(12) , 1743–1750 (2010).
- Chia CW , EganJM. Incretin-based therapies in Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab.93(10) , 3703–3716 (2008).
- Seino S , ZhangCL, ShibasakiT. Sulfonylurea action re-revisited. J. Diabetes Invest.1(1–2) , 37–39 (2010).
- Zhang CL , KatohM, ShibasakiT et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science 325(5940) , 607–610 (2009).
- Travers ME , McCarthyMI. Type 2 diabetes and obesity: genomics and the clinic. Hum. Genet.130(1) , 41–58 (2011).
▪ Website
- The Ministry of Health, Labour, and Welfare in Japan. Pharmaceuticals and Medical devices safety information. No. 275, December 2010 (In Japanese). www1.mhlw.go.jp/kinkyu/iyaku_j/iyaku_j/anzenseijyouhou/275.pdf